New Insights on INGREZZA's Benefits for Older Adults with TD
Recent findings regarding the use of INGREZZA® (valbenazine) capsules in treating tardive dyskinesia (TD) in older adults provide a refreshing perspective on mental health management. These new analyses highlight important improvements in patient-reported outcomes, emphasizing that treatment can have a profound impact on the quality of life for this demographic. With a growing body of evidence, INGREZZA stands out as a viable option for managing the symptoms of TD.
Understanding the Impact of Tardive Dyskinesia
Tardive dyskinesia is a disorder characterized by uncontrolled movements that can severely affect an individual's daily life. It often arises from long-term use of antipsychotic medications, impacting movement control due to altered dopamine signaling in the brain. It is estimated that over 800,000 adults in the U.S. are living with this condition, often suffering in silence while these involuntary movements disrupt their routines and social interactions.
The Importance of Quality of Life Studies
New analyses from a Phase 4 randomized withdrawal study have shed light on how INGREZZA can significantly enhance the health-related quality of life and functional status of adults aged 65 years and older afflicted with tardive dyskinesia. This study involved a cohort of 29 adults who were monitored over a randomized control period. Results were encouraging, demonstrating that patients who continued their treatment with INGREZZA experienced meaningful improvements compared to those who switched to a placebo.
Patient-Reported Outcomes Matter
The study employed two clinically validated assessment tools to collect data on patient-reported outcomes. The EuroQol 5-Dimension 5-Level (EQ-5D-5L) tool helped gauge improvements across several health dimensions, including mobility and emotional well-being. The Sheehan Disability Scale (SDS) was used to evaluate how these improvements corresponded to various life aspects such as work and social activities, giving a clear picture of how these improvements translate to daily living.
Sanjay Keswani's Perspective
Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, emphasized the findings, noting that older adults experiencing TD face increased risks of physical and social consequences due to their uncontrolled movements. The analyses reflected not only a robust improvement in health-related quality of life, but also underscored the accumulating evidence demonstrating INGREZZA's efficacy beyond merely alleviating movement disorders.
A Closer Look at INGREZZA's Mechanism
INGREZZA works by selectively inhibiting the vesicular monoamine transporter 2 (VMAT2) receptor. While the precise mechanisms remain under exploration, it is understood that INGREZZA’s specific targeting of dopamine release plays a central role in dampening the unwanted movements associated with tardive dyskinesia. Unique in its formulation, patients can start with a therapeutic dose right from the beginning without the need for titration.
Insights from the KINECT-PRO™ Study
The KINECT-PRO™ study has provided valuable data reinforcing the safety and efficacy of INGREZZA in older patients. This open-label study across a diverse patient population not only highlighted the drug's potential in real-world applications but also showcased the need for comprehensive measures to evaluate the impacts of medications on life quality.
Future Presentations and Research Directions
At the upcoming AANP National Conference, more presentations are scheduled to share findings related to real-world insights and meaningful long-term improvements in adults with tardive dyskinesia, further contributing to the landscape of treatment options available. These insights can potentially drive future research and guide clinicians in managing this complex condition with greater efficacy.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc., known for its commitment to neuroscience-focused biopharmaceutical development, strives to improve treatment protocols for those suffering from under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. With a robust portfolio of FDA-approved therapies that serve critical healthcare needs, the company continually invests in research and innovation aimed at enhancing patient outcomes.
Frequently Asked Questions
What is INGREZZA used for?
INGREZZA is used to treat adults with tardive dyskinesia and involuntary movements associated with Huntington's disease.
How does INGREZZA improve quality of life?
Studies show that INGREZZA significantly alleviates the symptoms of tardive dyskinesia, enhancing overall health-related quality of life for patients.
Are there side effects associated with INGREZZA?
Common side effects include sleepiness and tiredness. More serious side effects can occur, so it's essential to discuss them with a healthcare provider.
Who can take INGREZZA?
INGREZZA is specifically approved for use in adults with tardive dyskinesia and chorea associated with Huntington's disease.
Why is patient-reported data important in studies?
Patient-reported outcomes provide critical insights into how treatments affect patients’ everyday lives, beyond clinical metrics, ensuring a holistic approach to healthcare.
